Physician profile
Thomas Skelton
NPI 1174054605
$2,537.83
in general payments reported to CMS, 2019-2025
20 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.63 · 2022: $115 · 2023: $60.19 · 2024: $1,292 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $268.50 | 2021-2025 | |
| Novo Nordisk INC | $246.49 | 2024-2025 | Wegovy |
| Inspire Medical Systems, INC. | $219.80 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.77 | 2024-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $184.98 | 2025 | Evkeeza, Dupixent |
| Philips North America LLC | $179.40 | 2024-2025 | Lm Undivided, (Bh4) Igt Devices Undivided |
| Cvrx, INC. | $145.57 | 2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $135.64 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.67 | 2024-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $120.77 | 2024 | |
| Penumbra, INC. | $119.57 | 2024 | Indigo System |
| Boston Scientific Corporation | $111.73 | 2024 | Watchman Access System |
| Abiomed | $111.48 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $108.16 | 2025 | Tryvio |
| Astrazeneca Pharmaceuticals LP | $72.57 | 2024-2025 | Wainua |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procyrion, INC. | $57.65 | 2024-2025 | Aortix System |
| Merck Sharp & Dohme LLC | $48.38 | 2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.31 | 2024 | Lifevest |
| Bridgebio Pharma, INC. | $21.53 | 2025 | Attruby |
| Tricoast Surgical Solutions LLC | $15.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Skelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.